{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/malaria-prophylaxis/prescribing-information/chloroquine/","result":{"pageContext":{"chapter":{"id":"2f74fd56-68c0-56c8-a07c-22482e10e67e","slug":"chloroquine","fullItemName":"Chloroquine","depth":2,"htmlHeader":"<!-- begin field 54dd23b7-5904-48cc-a3a7-1495b0708917 --><h2>Chloroquine</h2><!-- end field 54dd23b7-5904-48cc-a3a7-1495b0708917 -->","summary":"","htmlStringContent":"<!-- begin item 8858072f-3866-4078-89d4-f32d1491e287 --><!-- begin field 653d4687-18fe-49e7-a6f6-a88e00c6567e --><ul><li><strong>Chloroquine is highly toxic in overdose</strong>.<ul><li>Overdose can be difficult to treat and life threatening (especially in children) due to arrhythmias (which can have a very rapid onset) and convulsions (which can be intractable).</li><li>If overdose occurs urgent advice from the National Poisons Information Service is essential.</li></ul></li><li><strong>Regimen</strong><ul><li>Chloroquine is the drug of choice for people travelling to areas with chloroquine-sensitive malaria (chloroquine-resistant malaria is widespread). Chloroquine:<ul><li>Is available as a syrup or tablets and usually taken as a single dose once a week, on the same day each week.</li><li>Should be started 1 week before entering an endemic area, continued throughout the time in the area and for 4 weeks after leaving the area.</li><li>Is considered safe for long term use but eye examinations every 6 to 12 months should be considered after 3 years’ use for malaria prophylaxis.</li></ul></li></ul></li><li><strong>Chloroquine is contraindicated in:</strong><ul><li>People with hypersensitivity to chloroquine or to any other ingredients in the formulation.</li><li>People with epilepsy.</li><li>People who are concomitantly taking amiodarone (there is an increased risk of ventricular arrhythmias).</li></ul></li><li><strong>Chloroquine should be used with caution in</strong>:<ul><li>Diabetes (severe hypoglycaemia has occurred in diabetics and non-diabetics).</li><li>People at risk of prolonged QT interval.</li><li>People with psoriasis or mayasthenia gravis — may exacerbate these conditions; avoid if possible.</li><li>Acute porphyrias — may precipitate severe symptoms.</li><li>G6PD deficiency — there may be a risk of haemolysis.</li><li>Renal impairment — chloroquine is only partially excreted by the kidneys and reduction of the dose is not needed except in severe impairment.</li><li>Hepatic impairment — use with caution in moderate to severe impairment.</li></ul></li><li><strong>Interactions</strong><ul><li>There is an increased risk of ventricular arrhythmias in people concomitantly taking drugs known to prolong the QT interval (such as antiarrhythmics, tricyclic antidepressants, antipsychotics, and some anti-infectives).</li><li>Other drugs that may interact with chloroquine include:<ul><li>Mefloquine — increased risk of convulsions.</li><li>Ciclosporin — increased risk of ciclosporin toxicity.</li><li>Digoxin — possibly increases plasma concentration of digoxin.</li><li>Dapsone — may increase the risk of methaemoglobinaemia.</li><li>Penicillamine — may increase the risk of haematological toxicity.</li></ul></li><li>Antacids may reduce the absorption of chloroquine — they should be taken at least 4 hours apart.</li><li>Chloroquine may suppress antibody response to intradermal human diploid cell rabies vaccine.<ul><li>This interaction has not been seen when rabies vaccine is given intramuscularly (the currently recommended mode of vaccination in the UK).</li><li>Post-vaccine rabies antibodies may need to be obtained to verify an adequate immunologic response.</li></ul></li></ul></li><li><strong>Adverse effects</strong><ul><li><strong>Chloroquine is very toxic (potentially fatal) in overdose </strong>— seek urgent advice from a Poison’s centre if this occurs. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/poisoning-or-overdose/\">Poisoning or overdose</a>.</li><li><strong>Common or very common adverse effects include</strong>:<ul><li>Gastro-intestinal disturbances; headache; pruritus; rash and skin reactions.</li></ul></li><li><strong>Uncommon adverse effects include</strong>:<ul><li>Convulsions; discoloration of mucous membranes, nails or skin; ECG changes; hair depigmentation or loss; keratopathy; ototoxicity; retinal damage; and visual change.</li></ul></li><li>Retinopathy has been associated with high doses of chloroquine (for example used in treatment of rheumatoid arthritis) but appears to be unlikely with doses used for routine malaria prophylaxis.</li></ul></li><li><strong>Children</strong><ul><li>Store safely away from children as overdose can be fatal. If overdose occurs urgent advice from the National Poisons Information Service is essential.</li><li>Chloroquine can be given from birth. The Public Health England Advisory Committee on Malaria Prevention (ACMP) and British National Formulary (BNF) dosages should be used.<ul><li>The dose steps for chloroquine syrup are not the same as for chloroquine tablets and a child may be prescribed a different dose of chloroquine depending on which preparation they take.</li></ul></li><li>Chloroquine has a bitter taste and may need mixed with food to encourage the child to take it.</li></ul></li><li><strong>Pregnancy and breastfeeding</strong><ul><li>The UK Teratology Information Service (UKTIS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">UKTIS, 2014a</a>] found no evidence (from limited available studies) that chloroquine use in pregnancy is associated with increased risk of structural malformation or other adverse outcomes such as spontaneous abortion, stillbirth or low infant birth weight.</li><li>UKTIS advise that where chloroquine is clinically indicated, it should not be withheld because of pregnancy as the risks of malaria infection in the mother and foetus are likely to outweigh potential foetal risks associated with use of chloroquine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">UKTIS, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CDC, 2018</a>]</p><!-- end field 653d4687-18fe-49e7-a6f6-a88e00c6567e --><!-- end item 8858072f-3866-4078-89d4-f32d1491e287 -->","topic":{"id":"1dfdf856-ced9-50bb-8739-9ac597e749da","topicId":"fcbcecf9-c37c-4236-a0f0-e6ea3ff72076","topicName":"Malaria prophylaxis","slug":"malaria-prophylaxis","lastRevised":"Last revised in January 2018","chapters":[{"id":"ce4f76aa-9527-5f8c-9846-98b8c95af6e4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6fd40a83-7b55-56f4-97de-93dd8ba2ad8f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"665f9f2c-5318-56d6-ac14-83dd936bdf97","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"62945b37-6310-5a07-b2dc-90e23836e367","slug":"changes","fullItemName":"Changes"},{"id":"57a7f2b1-f3c6-5c7c-be23-60a85ca3e97f","slug":"update","fullItemName":"Update"}]},{"id":"4cbf6005-cbd7-5792-be78-1e08b1755887","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24cd959e-2b4a-53d8-9a67-2cb6351480d4","slug":"goals","fullItemName":"Goals"},{"id":"8bfd8f1f-5162-55f5-98d0-024aa470eda3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3197bd-4c7e-50e3-8571-464b20b486e6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"68b0fb84-1d6e-5755-9c2e-89fd57721afa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e6ae722-735b-5e79-85d2-194cb8187380","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"66ce78ae-da4a-51bf-9d51-ae896236d71d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f8048c7c-b171-5f3b-91f0-2a353065712f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0f3bc680-088f-5879-bf5b-9cc85a3ea0ff","slug":"definition","fullItemName":"Definition"},{"id":"b849c9ff-c93f-5656-a227-098952e12f88","slug":"causes","fullItemName":"Causes"},{"id":"caad75c1-ac57-5c45-b040-8526b6235302","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ef83916a-1184-5356-93ba-f9bac26e167a","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a763547a-e2f3-5435-b3e5-36b2b8ad0c9e","slug":"complications","fullItemName":"Complications"}]},{"id":"254e9708-01a9-5862-801a-70f9e1fb5e84","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3379892e-94c0-5840-a578-cb5766212c69","slug":"assessment","fullItemName":"Assessment"},{"id":"4f391cab-b5f3-563e-be8a-a7235fe6467f","slug":"clinical-features","fullItemName":"Clinical features"}]},{"id":"18712f50-06cc-5638-9851-5c50e65488b5","fullItemName":"Management","slug":"management","subChapters":[{"id":"97193dc0-631b-5bea-89f3-7e605df7f3f4","slug":"malaria-prevention-in-travellers-from-the-uk","fullItemName":"Scenario: Malaria prevention in travellers from the UK"}]},{"id":"7750a127-e87f-5079-8777-0c8f13536296","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d4c5d3cf-2088-5d0a-94a1-af0994185aa5","slug":"drug-availability-on-the-nhs","fullItemName":"Drug availability on the NHS"},{"id":"f0cf5bcc-8534-50cf-a520-0e80e777e72d","slug":"prescribing-in-children","fullItemName":"Prescribing in children"},{"id":"2f74fd56-68c0-56c8-a07c-22482e10e67e","slug":"chloroquine","fullItemName":"Chloroquine"},{"id":"a6e70a24-4baa-514f-9d3a-a7ccb0d9b45c","slug":"proguanil","fullItemName":"Proguanil"},{"id":"2ce163bd-7fa7-51bd-8554-3a6a1cafdfa1","slug":"mefloquine","fullItemName":"Mefloquine"},{"id":"4ca8c124-4f45-50ce-a3b2-9a02219d6ab9","slug":"proguanil-plus-atovaquone","fullItemName":"Proguanil plus atovaquone"},{"id":"57e80cdf-fc37-5774-979d-f58301a7b5fb","slug":"doxycycline","fullItemName":"Doxycycline"}]},{"id":"38b67274-c723-5e50-9cdd-5cc01de962cb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91d3306b-2734-52a0-ac13-1adf3711008a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bb5bc365-9c32-5684-9333-e464e129ad67","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7b7d36b2-37d8-5815-836a-898e104a533e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2d5b97c9-c3d7-51bf-beae-65128d39bd5d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d69ddbc4-81c8-5404-8a15-7bc2502831cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c2fc1581-dd5f-5317-a19f-cfb72905246e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d7b5a2b6-f6a2-529e-8337-1780d8941d2c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7750a127-e87f-5079-8777-0c8f13536296","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}